[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 122
Citations 0
Capitol Health Call
August 8, 2012

Incentives for New Antibiotics

JAMA. 2012;308(6):558. doi:10.1001/jama.2012.9558

Final congressional passage of the Food and Drug Administration (FDA) Safety and Innovation Act is expected to renew interest in antibiotic research and development.

The legislation (S 3187; http://tinyurl.com/7kz57hk) primarily requires drug and device manufacturers to pay user fees to fund the FDA's approval process for drugs and medical devices. But some of the fees are earmarked to bolster the agency's safety oversight and to pay for other programs, such as creating incentives for antibiotic development.